Ascendis Pharma Q4 2025 Earnings Preview
Source: SeekingAlpha
2026-02-10 17:35:51 ET
More on Ascendis Pharma
- Ascendis: Why I'm Skeptical On Takeover Rumors, Long-Term Targets
- Ascendis Pharma A/S (ASND) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript
- Ascendis Pharma rises amid takeover speculation
- Ascendis dwarfism drug candidate review extended by FDA
Read the full article on Seeking Alpha
For further details see:
Ascendis Pharma Q4 2025 Earnings Preview
Ascendis Pharma A/S
NASDAQ: ASND
ASND Trading
1.29% G/L:
$241.61 Last:
166,300 Volume:
$239.73 Open:
ASND Latest News
March 02, 2026 08:43:00 am
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference
February 27, 2026 05:57:16 pm
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older
ASND Stock Data
$13,394,473,228
60,082,592
N/A
105
N/A
Biotechnology & Life Sciences
Healthcare
DK
Hellerup
